Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
Public ClinicalTrials.gov record NCT01004432. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of switching rheumatoid arthritis (RA) participants who have an inadequate response to their current treatment with either etanercept + methotrexate or adalimumab + methotrexate to treatment with golimumab 50 milligram (mg) subcutaneous (SC) injection (a needle inserted under the skin in the back of upper arm, upper thigh or stomach area) every 4 weeks + methotrexate. This study is also designed to evaluate the benefit and safety of switching participants from treatment with golimumab 50 mg subcutaneous injection every 4 weeks + methotrexate to golimumab 2 milligram per kilogram (mg/kg) intravenous every 8 weeks + methotrexate, for those who do not achieve a marked improvement of their RA at Week 16.
Study identification
- NCT ID
- NCT01004432
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 433 participants
Conditions and interventions
Conditions
Interventions
- Golimumab 50 mg SC Drug
- Golimumab 2 mg/kg IV Drug
- Methotrexate (MTX) Drug
- Placebo SC Drug
- Placebo IV Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2009 (Type not available)
- Primary completion
- Jul 2013 (Actual)
- Completion
- Oct 2013 (Actual)
- Last update posted
- Apr 30, 2015
2009 – 2013
United States locations
- U.S. sites
- 89
- U.S. states
- 33
- U.S. cities
- 89
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Tuscaloosa | Alabama | — | — |
| Not listed | Mesa | Arizona | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Hot Springs | Arkansas | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Covina | California | — | — |
| Not listed | Hemet | California | — | — |
| Not listed | Loma Linda | California | — | — |
| Not listed | Long Beach | California | — | — |
| Not listed | Murrieta | California | — | — |
| Not listed | Santa Maria | California | — | — |
| Not listed | Santa Monica | California | — | — |
| Not listed | Torrance | California | — | — |
| Not listed | Van Nuys | California | — | — |
| Not listed | Victorville | California | — | — |
| Not listed | Whittier | California | — | — |
| Not listed | Bridgeport | Connecticut | — | — |
| Not listed | Hamden | Connecticut | — | — |
| Not listed | Trumbull | Connecticut | — | — |
| Not listed | Aventura | Florida | — | — |
| Not listed | Fort Lauderdale | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Naples | Florida | — | — |
| Not listed | Orange Park | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Palm Harbor | Florida | — | — |
| Not listed | Plantation | Florida | — | — |
| Not listed | Sarasota | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Duluth | Georgia | — | — |
| Not listed | Coeur d'Alene | Idaho | — | — |
| Not listed | Idaho Falls | Idaho | — | — |
| Not listed | Rockford | Illinois | — | — |
| Not listed | South Bend | Indiana | — | — |
| Not listed | Bettendorf | Iowa | — | — |
| Not listed | Kansas City | Kansas | — | — |
| Not listed | Bowling Green | Kentucky | — | — |
| Not listed | Monroe | Louisiana | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Wheaton | Maryland | — | — |
| Not listed | Rochester | Minnesota | — | — |
| Not listed | Flowood | Mississippi | — | — |
| Not listed | Tupelo | Mississippi | — | — |
| Not listed | Clayton | Missouri | — | — |
| Not listed | Florissant | Missouri | — | — |
| Not listed | Lincoln | Nebraska | — | — |
| Not listed | Freehold | New Jersey | — | — |
| Not listed | Brooklyn | New York | — | — |
| Not listed | Mineola | New York | — | — |
| Not listed | Plainview | New York | — | — |
| Not listed | Rochester | New York | — | — |
| Not listed | Smithtown | New York | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Greenville | North Carolina | — | — |
| Not listed | Hickory | North Carolina | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Akron | Ohio | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Mayfield | Ohio | — | — |
| Not listed | Middleburg Heights | Ohio | — | — |
| Not listed | Edmond | Oklahoma | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Lake Oswego | Oregon | — | — |
| Not listed | Bethlehem | Pennsylvania | — | — |
| Not listed | Duncansville | Pennsylvania | — | — |
| Not listed | West Reading | Pennsylvania | — | — |
| Not listed | Wexford | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Myrtle Beach | South Carolina | — | — |
| Not listed | Hixson | Tennessee | — | — |
| Not listed | Jackson | Tennessee | — | — |
| Not listed | Kingsport | Tennessee | — | — |
| Not listed | Knoxville | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Carrollton | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Arlington | Virginia | — | — |
| Not listed | Chesapeake | Virginia | — | — |
| Not listed | Seattle | Washington | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Beckley | West Virginia | — | — |
| Not listed | Clarksburg | West Virginia | — | — |
| Not listed | Glendale | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01004432, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2015 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01004432 live on ClinicalTrials.gov.